Page last updated: 2024-12-07

3-quinuclidinyl-4-iodobenzilate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

3-Quinuclidinyl-4-iodobenzilate (QNB) is a potent and selective muscarinic acetylcholine receptor antagonist. It is a synthetic compound with a high affinity for the M1 subtype of muscarinic receptors. QNB has been used as a research tool to study the role of muscarinic receptors in various physiological processes, including memory, cognition, and smooth muscle function. It has also been studied for its potential therapeutic applications in treating conditions such as Alzheimer's disease and Parkinson's disease. The synthesis of QNB typically involves the reaction of a quinuclidine derivative with a 4-iodobenzilate derivative. The effects of QNB are primarily mediated through its antagonism of muscarinic receptors. It can block the binding of acetylcholine to these receptors, leading to a range of physiological effects, including inhibition of glandular secretions, relaxation of smooth muscle, and alteration of central nervous system function. QNB is a potent anticholinergic agent, and its use is typically restricted to research settings due to its significant side effects. QNB is studied because it provides a valuable tool for investigating the role of muscarinic receptors in various physiological processes. Its high affinity and selectivity for M1 receptors make it particularly useful for understanding the function of this specific receptor subtype. Furthermore, the potential therapeutic applications of QNB in treating neurological disorders have motivated ongoing research.'

Cross-References

ID SourceID
PubMed CID122241
CHEMBL ID275313
SCHEMBL ID8529194
MeSH IDM0119501

Synonyms (18)

Synonym
benzeneacetic acid, alpha-hydroxy-4-(iodo-125i)-alpha-phenyl-, 1-azabicyclo(2.2.2)oct-3-yl ester
CHEMBL275313
81381-93-3
1-azabicyclo[2.2.2]octan-3-yl 2-hydroxy-2-(4-iodophenyl)-2-phenylacetate
3-quinuclidinyl-4-(125)iodobenzilate
4-iqnb
3-quinuclidinyl-4-iodobenzilate
1-azabicyclo(2.2.2)oct-3-yl alpha-hydroxy-alpha-(4-iodophenyl)-alpha-phenylacetate
1-ahip
iodine-123-iqnb
3-quinuclidinyl 4-iodobenzilate
SCHEMBL8529194
MHBGDNWDRYOZPX-UHFFFAOYSA-N
hydroxy-diphenacetic acid, 4-iodo-, (1,4-ethano)piperidinyl ester
1-azabicyclo[2.2.2]oct-3-yl hydroxy(4-iodophenyl)phenylacetate #
[(3s)-1-azabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-(4-iodophenyl)-2-phenylacetate
DTXSID601001958
1-azabicyclo[2.2.2]octan-3-yl hydroxy(4-iodophenyl)phenylacetate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID226399Muscarinic receptor binding comparison to QNB, Relative binding index(RBI)1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Analogues of 3-quinuclidinyl benzilate.
AID142898Inhibition of (-)-[3H]-QNB muscarinic acetylcholine receptor binding on rat/ dog ventricular muscle1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Analogues of 3-quinuclidinyl benzilate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (27.03)18.7374
1990's20 (54.05)18.2507
2000's7 (18.92)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.68 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (10.81%)5.53%
Reviews1 (2.70%)6.00%
Case Studies2 (5.41%)4.05%
Observational0 (0.00%)0.25%
Other30 (81.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]